[go: up one dir, main page]

ES2571127T3 - Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos - Google Patents

Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos

Info

Publication number
ES2571127T3
ES2571127T3 ES11788227T ES11788227T ES2571127T3 ES 2571127 T3 ES2571127 T3 ES 2571127T3 ES 11788227 T ES11788227 T ES 11788227T ES 11788227 T ES11788227 T ES 11788227T ES 2571127 T3 ES2571127 T3 ES 2571127T3
Authority
ES
Spain
Prior art keywords
particles
target molecules
separation
samples containing
fibrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11788227T
Other languages
English (en)
Inventor
Amar Rida
Nicolas Mermod
Patrice Francois
Vladimir Lazarevic
Jacques Schrenzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Debiopharm International SA
Original Assignee
Debiopharm International SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm International SA filed Critical Debiopharm International SA
Application granted granted Critical
Publication of ES2571127T3 publication Critical patent/ES2571127T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/56938Staphylococcus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/14Streptococcus; Staphylococcus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/75Fibrin; Fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974Thrombin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Método para el procesamiento de una muestra líquida que comprende fibrinógeno, para la separación y concentración de moléculas o partículas objetivo de la muestra, que comprende: a. Atrapar dichas moléculas o partículas objetivo en una red de fibrina sometiendo la muestra a trombina o enzimas de tipo trombina para convertir, como mínimo, parcialmente el fibrinógeno contenido en la dicha muestra en fibrina para formar la red de fibrina b. Retraer dicha red de fibrina para formar un coágulo de fibrina c. Separar de dicho coágulo de fibrina del medio de muestra circundante.
ES11788227T 2010-09-15 2011-09-15 Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos Active ES2571127T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH14782010 2010-09-15
CH20412010 2010-12-07
CH12072011 2011-07-20
PCT/IB2011/054035 WO2012035508A2 (en) 2010-09-15 2011-09-15 Method for separating target molecules or particles from fibrinogen-containing samples including blood components

Publications (1)

Publication Number Publication Date
ES2571127T3 true ES2571127T3 (es) 2016-05-24

Family

ID=45044632

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11788227T Active ES2571127T3 (es) 2010-09-15 2011-09-15 Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos
ES16154770T Active ES2751660T3 (es) 2010-09-15 2011-09-15 Dispositivo que incluye componentes sanguíneos para separar moléculas o partículas diana de muestras

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES16154770T Active ES2751660T3 (es) 2010-09-15 2011-09-15 Dispositivo que incluye componentes sanguíneos para separar moléculas o partículas diana de muestras

Country Status (17)

Country Link
US (4) US9689881B2 (es)
EP (2) EP2616550B1 (es)
JP (1) JP5999776B2 (es)
KR (1) KR101948944B1 (es)
CN (2) CN107389932B (es)
AU (2) AU2011303467C1 (es)
CA (1) CA2811493C (es)
CY (1) CY1122166T1 (es)
DK (2) DK2616550T3 (es)
ES (2) ES2571127T3 (es)
HR (1) HRP20191785T1 (es)
HU (2) HUE028915T2 (es)
LT (1) LT3067431T (es)
PL (2) PL3067431T3 (es)
PT (1) PT3067431T (es)
SI (1) SI3067431T1 (es)
WO (1) WO2012035508A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3067431T (lt) 2010-09-15 2019-11-11 Debiopharm Int Sa Įrenginys, turintis kraujo komponentus, skirtas atskirti tikslines molekules ar daleles iš mėginių
CN108671224B (zh) 2011-06-27 2022-12-13 爱默蕾大学 血小板裂解物的组合物、用途和制备
EP2979093B1 (en) * 2013-03-29 2019-10-23 Siemens Healthcare Diagnostics Inc. Rare cell concentration
SI3148698T1 (sl) * 2014-06-01 2019-09-30 Debiopharm International Sa Forum "Apres-Demain" Naprava za jemanje in obdelavo vzorcev
US12397302B2 (en) 2015-11-30 2025-08-26 Dh Technologies Development Pte. Ltd. Electromagnetic assemblies for processing fluids
US10596236B2 (en) 2016-03-10 2020-03-24 Arthrex, Inc. Systems and methods for preparing a thrombin serum
EP3426400B1 (en) 2016-03-10 2020-09-02 Arthrex Inc System for preparing protein enhanced serums
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
JP7298449B2 (ja) * 2019-11-14 2023-06-27 株式会社島津製作所 血液凝固分析装置、及び分注ノズルの洗浄方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1035260A (en) * 1974-08-12 1978-07-25 Baxter Travenol Laboratories Collection and processing tube
FR2625321B1 (fr) * 1987-12-24 1992-10-02 Pasteur Institut Reactif pour le diagnostic de staphylococcus aureus par agglutination
DE3803463A1 (de) * 1988-02-05 1989-08-17 Linhart Axel Semiquantitativer kalzium-schnelltest
EP0325106B1 (de) * 1988-01-05 1992-10-21 Axel Dr. Linhart Verfahren und Test-Kit zur semiquantitativen Bestimmung des Kalziumgehaltes im Blut
US5691160A (en) * 1992-08-14 1997-11-25 Biogen, Inc. Effects of actin filaments of fibrin clot structure and lysis
DE69316293T2 (de) * 1992-09-09 1998-08-27 Tokuyama Corp Methode zur Bestimmung von Fibrinogen, trockenes Reagens hierfür und Verfahren zur Herstellung desselben
JP3292760B2 (ja) * 1993-04-22 2002-06-17 テルモ株式会社 採血管およびその製造方法
US5670329A (en) * 1993-05-28 1997-09-23 Cardiovascular Diagnostics, Inc. Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field
CA2176810A1 (en) 1993-12-03 1995-06-08 Gordon L. Dorn Method for improving quantitative recovery of microorganisms from speci mens containing blood components
DE19602673A1 (de) * 1996-01-25 1997-08-07 Pereg Gmbh Synthetische Testanschmutzung
US6121232A (en) * 1997-01-31 2000-09-19 Omrix Biopharmaceuticals Sa Stabilized mixture comprising fibrinogen
US6680195B1 (en) * 1997-11-26 2004-01-20 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
JP2000262499A (ja) * 2000-01-01 2000-09-26 Terumo Corp 採血管
US6686204B2 (en) * 2001-08-27 2004-02-03 Becton, Dickinson & Company Collection device
JP2005508925A (ja) * 2001-10-03 2005-04-07 クリストファー ジェイ ウールヴァートン 貯蔵安定なフィブリノーゲン溶液
EP1504269B1 (en) * 2002-05-01 2007-07-25 Synapse B.V. Diagnostic test for determining the concentration of transient proteolytic activity in composite biological media
WO2005021799A2 (en) * 2003-08-15 2005-03-10 University Of South Florida Materials and methods for capture of pathogens and removal of aurintricarboxylic acid from a sample
ATE335816T1 (de) 2002-09-18 2006-09-15 Sirs Lab Gmbh Verfahren zum nachweis prokaryontischer dna
US20050065454A1 (en) * 2003-09-22 2005-03-24 Becton, Dickinson And Company Non-evacuated blood collection tube
US7399609B2 (en) * 2003-12-30 2008-07-15 3M Innovative Properties Company Staphylococcus detection
US8419722B2 (en) * 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
DE102005009479A1 (de) 2005-03-02 2006-09-07 Molzym Gmbh & Co. Kg Verwendung von Nukleasen zum Abbau von Nukleinsäure in Gegenwart von chaotropen Agenzien und/oder Tensiden
US20100009409A1 (en) * 2005-07-29 2010-01-14 Ecole Polytechnique Federale De Lausanne Molecular variant fibrinogen fusion proteins
ES2387700T3 (es) * 2007-05-03 2012-09-28 Accumetrics, Inc. Métodos para medir la inhibición de la agregación de plaquetas mediante antagonistas del receptor de trombina
EP2185681B1 (en) 2007-08-02 2014-12-17 Université Laval Concentration and enrichment of microbial cells and microbial nucleic acids from bodily fluids
JP5029217B2 (ja) * 2007-08-27 2012-09-19 東レ株式会社 シート状物の製造方法
PL2310411T3 (pl) * 2008-07-09 2017-02-28 Profibrix Bv Rekombinowany fibrynogen
AU2010272505B2 (en) 2009-07-16 2015-09-17 Glaxosmithkline Biologicals S.A. Treatment of infections
LT3067431T (lt) 2010-09-15 2019-11-11 Debiopharm Int Sa Įrenginys, turintis kraujo komponentus, skirtas atskirti tikslines molekules ar daleles iš mėginių

Also Published As

Publication number Publication date
PL2616550T3 (pl) 2016-08-31
EP2616550B1 (en) 2016-02-10
KR20130107300A (ko) 2013-10-01
ES2751660T3 (es) 2020-04-01
US20130164737A1 (en) 2013-06-27
PL3067431T3 (pl) 2019-12-31
CN103108959A (zh) 2013-05-15
LT3067431T (lt) 2019-11-11
DK3067431T3 (da) 2019-10-14
CA2811493A1 (en) 2012-03-22
CN103108959B (zh) 2017-06-09
CN107389932B (zh) 2019-11-22
US20210148940A1 (en) 2021-05-20
EP3067431B1 (en) 2019-07-24
SI3067431T1 (sl) 2019-11-29
WO2012035508A4 (en) 2012-07-19
HRP20191785T1 (hr) 2019-12-27
AU2011303467C1 (en) 2017-03-09
DK2616550T3 (en) 2016-05-23
CN107389932A (zh) 2017-11-24
EP3067431A1 (en) 2016-09-14
KR101948944B1 (ko) 2019-02-15
AU2016266066A1 (en) 2016-12-22
US9689881B2 (en) 2017-06-27
EP2616550A2 (en) 2013-07-24
HUE045771T2 (hu) 2020-01-28
CA2811493C (en) 2020-06-16
AU2011303467B2 (en) 2016-09-15
WO2012035508A3 (en) 2012-05-18
AU2011303467A1 (en) 2013-04-04
JP5999776B2 (ja) 2016-09-28
US20170336424A1 (en) 2017-11-23
CY1122166T1 (el) 2020-11-25
PT3067431T (pt) 2019-10-29
HK1247280A1 (zh) 2018-09-21
US20240280593A1 (en) 2024-08-22
WO2012035508A2 (en) 2012-03-22
HUE028915T2 (en) 2017-01-30
AU2016266066B2 (en) 2017-12-21
JP2013538355A (ja) 2013-10-10

Similar Documents

Publication Publication Date Title
ES2571127T3 (es) Método para la separación de moléculas o partículas objetivo a partir de muestras que contienen fibrinógeno, incluyendo componentes sanguíneos
GB2519906A (en) Methods and systems for detecting biological components
BR112013025758A2 (pt) monitoramento de misturas de amplificação de recombinase polimerase
WO2013126774A3 (en) Microfluidic devices for capture of target species
CR20120326A (es) Dispositivo portátil de monitorización de la coagulación y método de evaluación de la respuesta de coagulación
EA201491833A1 (ru) Основанные на клетках перекрестные анализы и их применение
TR201906285T4 (tr) İntraoperatif otolog kan kurtarımından tümör hücrelerinin giderilmesi.
MX2021003761A (es) Centrifuga compacta de alta velocidad para utilizarse con peque?os volumenes de muestra.
BR112014010718A2 (pt) métodos e sistemas para detecção de analito em amostra
WO2013190075A3 (en) Specific biomarkers for hepatocellular carcinoma (hcc)
WO2012122564A3 (en) Diagnostic and sample preparation devices and methods
MX351846B (es) Preparacion de suero.
MX358997B (es) Metodo para evaluar la reaccion de coagulacion sanguinea.
EA201291396A1 (ru) Способ детекции молекулярных взаимодействий
EA201490823A1 (ru) Агенты, реверсирующие действие антикоагулянтов
WO2012040603A3 (en) Use of diazolidinyl urea for anti-clumping of biological samples
CY1123698T1 (el) Εμπλουτισμος κυκλοφορουντων κυτταρων ογκου μεσω εξαντλησης λευκων αιμοσφαιριων
PE20190517A1 (es) Preparacion farmaceutica antienvejecimiento
WO2010011358A3 (en) Method and medium for detecting the presence or absence of staphylococcus aureus in a test sample
IN2015DN01608A (es)
BR112014015424A2 (pt) detecção de células derivadas de tecido do cordão umbilical humano
WO2014184684A3 (en) Methods and biomarkers for detection of hematological cancers
CL2014002976A1 (es) Metodo de analisis de una muestra biologica de un sujeto con cancer utilizando biomarcadores tnf, ripk1, cxl10, ccl5, nfkbia, herc5, cdyl, stk39 y mapk14 para la terapia inhibitoria con iap.
PL403996A1 (pl) Sposób jednoczesnej detekcji bakterii i grzybów w preparacie biologicznym metodą PCR, startery oraz zestaw do detekcji bakterii i grzybów
WO2012015219A3 (en) Real-time monitoring of depletion of high-abundance blood proteins or recovery of low-abundance blood proteins by uv spectrometry